Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SONN logo SONN
Upturn stock ratingUpturn stock rating
SONN logo

Sonnet Biotherapeutics Holdings Inc (SONN)

Upturn stock ratingUpturn stock rating
$1.12
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: SONN (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $20

1 Year Target Price $20

Analysts Price Target For last 52 week
$20Target price
Low$1.08
Current$1.12
high$8.72

Analysis of Past Performance

Type Stock
Historic Profit -25.39%
Avg. Invested days 23
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.93M USD
Price to earnings Ratio -
1Y Target Price 20
Price to earnings Ratio -
1Y Target Price 20
Volume (30-day avg) 1
Beta 0.94
52 Weeks Range 1.08 - 8.72
Updated Date 07/1/2025
52 Weeks Range 1.08 - 8.72
Updated Date 07/1/2025
Dividends yield (FY) -
Basic EPS (TTM) -12.07

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -1378.09%

Management Effectiveness

Return on Assets (TTM) -176.75%
Return on Equity (TTM) -714.97%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1988424
Price to Sales(TTM) 3.93
Enterprise Value 1988424
Price to Sales(TTM) 3.93
Enterprise Value to Revenue 1.99
Enterprise Value to EBITDA -0.21
Shares Outstanding 3165810
Shares Floating 3133076
Shares Outstanding 3165810
Shares Floating 3133076
Percent Insiders 1.53
Percent Institutions 5.24

Analyst Ratings

Rating 1
Target Price 20
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Sonnet Biotherapeutics Holdings Inc

stock logo

Company Overview

overview logo History and Background

Sonnet Biotherapeutics Holdings Inc. is a biotechnology company focused on developing innovative therapies for oncology and other diseases. Founded to leverage its Fully Human Albumin Binding (FHAB) technology, the company aims to improve drug delivery and efficacy. While precise founding year and detailed milestones were unavailable, its evolution is marked by preclinical and clinical programs focused on targeted drug delivery.

business area logo Core Business Areas

  • Oncology Therapeutics: Development of immunotherapeutic and targeted therapies for various cancers, leveraging their FHAB technology platform.
  • FHAB Technology Platform: Licensing and development of therapeutic candidates based on its Fully Human Albumin Binding (FHAB) technology platform, enhancing drug bioavailability and tumor targeting.

leadership logo Leadership and Structure

The leadership team consists of experienced professionals in biotechnology, including a CEO, CSO, and CFO. Organizational structure is typical of a clinical-stage biotech company, with departments for research and development, clinical operations, and finance.

Top Products and Market Share

overview logo Key Offerings

  • SON-1010 (IL-12-FHAB): A clinical-stage candidate utilizing FHAB technology to deliver IL-12 to the tumor microenvironment. Currently in clinical trials for various cancers. Market share data is unavailable as it is pre-commercialization. Competitors include companies developing IL-12 therapies and other cancer immunotherapies like Merck (KEYTRUDA) and Bristol Myers Squibb (OPDIVO).
  • SON-080 (IL-6-FHAB): Another clinical-stage candidate utilizing FHAB to deliver IL-6 to the tumor microenvironment for hematopoiesis. Competitors include companies developing treatments for chemotherapy induced hematopoiesis.

Market Dynamics

industry overview logo Industry Overview

The biotechnology industry is characterized by high innovation, long development timelines, and significant regulatory hurdles. Oncology is a major area of focus, with increasing demand for targeted therapies and immunotherapies.

Positioning

Sonnet Biotherapeutics positions itself as an innovator in targeted drug delivery using its FHAB technology, aiming to improve efficacy and reduce toxicity of cancer therapies. Their competitive advantage lies in the FHAB platform's potential to enhance drug bioavailability and tumor targeting.

Total Addressable Market (TAM)

The total addressable market for cancer therapeutics is estimated to be hundreds of billions of dollars. Sonnet is positioned to capture a portion of this TAM through successful development and commercialization of its FHAB-based therapies, focusing on niche areas like IL-12 and IL-6 targeted delivery. TAM is dependent on specific indications and success of clinical trials.

Upturn SWOT Analysis

Strengths

  • Proprietary FHAB technology platform
  • Clinical-stage therapeutic candidates
  • Experienced leadership team

Weaknesses

  • Limited financial resources
  • Dependence on clinical trial success
  • No currently approved products

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion into new therapeutic areas
  • Positive clinical trial results leading to accelerated approval

Threats

  • Clinical trial failures
  • Competition from established pharmaceutical companies
  • Regulatory hurdles
  • Difficulty raising capital

Competitors and Market Share

competitor logo Key Competitors

  • MRK
  • BMY
  • NVO

Competitive Landscape

Sonnet Biotherapeutics faces intense competition from established pharmaceutical companies with greater resources. Its FHAB technology offers a potential competitive advantage if clinical trials demonstrate superior efficacy and safety.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by research and development progress rather than revenue generation.

Future Projections: Future growth is contingent on successful clinical trials and potential partnerships. Analyst estimates are dependent on clinical trial outcomes.

Recent Initiatives: Recent initiatives include advancing clinical trials for SON-1010 and SON-080, securing funding through equity offerings, and exploring potential partnerships.

Summary

Sonnet Biotherapeutics is a clinical-stage company with a promising FHAB technology platform. It has the potential to improve targeted drug delivery and efficacy. However, it faces significant challenges including limited financial resources, clinical trial risks, and competition from larger pharmaceutical companies. Positive clinical trial outcomes and strategic partnerships are crucial for its success.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Industry Reports
  • Yahoo Finance
  • Seeking Alpha

Disclaimers:

The data provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is based on available information and estimates, and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Sonnet Biotherapeutics Holdings Inc

Exchange NASDAQ
Headquaters Princeton, NJ, United States
IPO Launch date 2006-10-31
Interim CEO & Director Mr. Raghu Rao
Sector Healthcare
Industry Biotechnology
Full time employees 13
Full time employees 13

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 to treat chemotherapy-induced peripheral neuropathy (CIPN), and diabetic peripheral neuropathy; SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer; SON-1411, a bifunctional combination of human interleukin 18 (IL-18) inhibitor binding protein and single-chain human IL-12 (IL-12) for solid tumor cancers; and SON-1400, a monofunctional fusion protein comprising the IL-18 binding protein resistant domain linked to the FHAB. It has a license agreement with New Life Therapeutics Pte, Ltd. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.